Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?
NCT ID NCT07634380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest dose of sitagliptin, then test how well the combination works in 64 participants. It is a small, early study focused on safety and dosing, not a proven treatment yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sitagliptin and pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a very early, small phase 1 trial focused on safety and dosing, so it is uncertain whether the combination will actually shrink tumors or improve outcomes. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••